Celltrion Pharm, Inc.
Financials
Valuation Metrics
Celltrion Pharm, Inc.'s Market Cap is ₩1.8T. At end of 2025 it was ₩2.6T. Ranked #243 of 2,420 in KR market (top 10%), #60 of 1,639 on KOSDAQ (top 4%), #23 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.78T KRW | KR#243/2,420 Sec#23/231 |
| Revenue | 577.99B KRW | KR#573/2,420 Sec#28/231 |
| Net Income | 42.88B KRW | KR#468/2,420 Sec#29/231 |
| Total Assets | 779.18B KRW | KR#565/2,420 Sec#32/231 |
| Net Assets | 449.20B KRW | KR#553/2,420 Sec#33/231 |
| Employees | 920 | KR#277/2,420 Sec#22/231 |
| Value | ||
| P/E | 41.42x | KR#1,365/2,420 Sec#85/231 |
| P/B | 3.95x | KR#2,166/2,420 Sec#177/231 |
| PEG | 1.36x | KR#768/2,420 Sec#49/231 |
| P/S | 3.07x | KR#1,968/2,420 Sec#121/231 |
| EV/EBITDA | 30.08x | KR#1,172/2,420 Sec#73/231 |
| FCF Yield | 3.96% | KR#900/2,420 Sec#52/231 |
| Profitability | ||
| ROE | 9.55% | KR#653/2,420 Sec#45/231 |
| ROA | 5.50% | KR#680/2,420 Sec#56/231 |
| Op. Margin | 10.73% | KR#480/2,420 Sec#43/231 |
| Revenue Growth | 13.88% | KR#724/2,420 Sec#71/231 |
| Earnings Growth | 30.36% | KR#647/2,420 Sec#43/231 |
| Financial Health | ||
| Debt Ratio | 73.46% | KR#1,263/2,420 Sec#151/231 |
| Total Debt | 142.00B KRW | KR#620/2,420 Sec#36/231 |
| FCF | 70.27B KRW | KR#238/2,420 Sec#14/231 |
| Cash | 51.70B KRW | KR#716/2,420 Sec#40/231 |
| Current Ratio | 1.71x | KR#1,027/2,420 Sec#115/231 |
| Net Debt/EBITDA | 1.46x | KR#785/2,420 Sec#54/231 |
| Dividend | ||
| Div. Yield | 0.49% | KR#1,248/2,420 Sec#77/231 |
| Performance | ||
| 1Y Return | -24.60% | KR#1,587/2,420 Sec#122/231 |
| 1M Return | -1.36% | KR#1,969/2,420 Sec#174/231 |
| From 52W High | -48.91% | KR#1,518/2,420 Sec#120/231 |
| 1Y MDD | -49.80% | KR#990/2,420 Sec#82/231 |
| Trading | ||
| Volume | 40,569 shares | KR#830/2,420 Sec#75/231 |
| Trading Value | 1.62B KRW | KR#448/2,420 Sec#44/231 |
| Foreign Own. | 4.83% | KR#882/2,420 Sec#79/231 |
| Per Share | ||
| EPS | 966 KRW | KR#735/2,420 Sec#50/231 |
| BPS | 10,117 KRW | KR#994/2,420 Sec#69/231 |
Company Info
This specialized pharmaceutical manufacturing and sales company was established in 2000 and listed on KOSDAQ in 2006. It operates KGMP, US cGMP, and EU-GMP certified facilities in Ochang and Jincheon, Chungcheongbuk-do, producing specialized pharmaceuticals and biopharmaceuticals via PFS production lines. The company holds domestic exclusive sales rights for chemical pharmaceuticals like the liver disease treatment Godex, and 12 biopharmaceuticals, including autoimmune disease treatments and anti-cancer drugs developed by its parent company, Celltrion, while actively pursuing pipeline expansion and technological platform innovation.